Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence
Metabolism and Target Organ Damage,
Год журнала:
2025,
Номер
5(1)
Опубликована: Март 27, 2025
Fatty
liver
disease
associated
with
metabolic
dysfunction
has
emerged
as
a
significant
global
health
challenge.
This
condition
often
coexists
other
diseases,
such
alcohol-related
and
viral
hepatitis,
complicating
both
diagnosis
management.
To
address
the
limitations
of
non-alcoholic
fatty
(NAFLD)
classification,
two
alternative
frameworks
have
been
proposed:
dysfunction-associated
(MAFLD)
in
2020
steatotic
(MASLD)
2023.
A
key
difference
between
these
definitions
is
how
they
consider
relation
to
coexistence
conditions.
MAFLD
adopts
dual
etiology
concept,
creating
unified
classification
system
that
aligns
contemporary
clinical
epidemiological
needs.
In
contrast,
MASLD
introduces
new
term,
MetALD
(metabolic
alcohol-related/associated
disease),
describe
patients
who
excessive
alcohol
intake.
review
critically
examines
clinical,
research,
implications
differing
approaches
MASLD,
offering
insights
into
their
potential
enhance
understanding
management
multi-etiology
diseases.
Язык: Английский
Metabolic dysfunction and Kidney Disease Risk in Individuals with MAFLD
Annals of Hepatology,
Год журнала:
2025,
Номер
unknown, С. 101910 - 101910
Опубликована: Март 1, 2025
Язык: Английский
Underrepresentation of Arabs in Functional Genetics Studies: Opportunities and Obstacles for Advancing Biology and Human Health
Liver International,
Год журнала:
2025,
Номер
45(5)
Опубликована: Апрель 4, 2025
A
significant
challenge
to
the
transnational
application
of
genetics
and
functional
genomic
studies
is
underrepresentation
certain
populations.
In
this
work,
we
emphasise
that
while
there
are
over
500
million
Arabs
living
across
22
countries,
they
largely
underrepresented
in
genetic
studies.
Remarkably,
only
0.96%
Genome-Wide
Association
Studies
(GWAS)
include
Arab
participants.
This
trend
also
apparent
various
other
databases,
which
not
limit
biological
discoveries
but
exacerbate
health
inequity.
To
address
urgent
issue,
propose
a
comprehensive
roadmap
aimed
at
effectively
integrating
population
into
research.
strategy
includes
creating
regional
biobanks
establishing
advanced
research
programs
translational
genomics,
as
well
fostering
greater
collaboration.
Ultimately,
approach
will
pave
way
for
more
effective
precision
medicine
equity
beyond.
Язык: Английский
MAFLD vs. MASLD: a year in review
Expert Review of Endocrinology & Metabolism,
Год журнала:
2025,
Номер
unknown, С. 1 - 12
Опубликована: Апрель 12, 2025
In
2023,
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
was
introduced
following
fatty
(MAFLD).
Both
aim
to
address
the
limitations
of
nonalcoholic
(NAFLD).
This
review
analyzes
similarities
and
differences
between
MAFLD
MASLD,
focusing
on
their
impacts
epidemiology,
diagnosis,
stigma,
related
diseases.
Current
evidence
suggests
that
criteria
effectively
identify
individuals
at
higher
risk
through
a
good
balance
sensitivity
specificity.
Moreover,
is
more
generalizable
term
easily
understood
globally.
The
transition
from
NAFLD
MASLD
marks
significant
advance
in
understanding
within
hepatology.
identifies
homogeneous
cohort
patients
with
due
dysfunction
provides
valuable
framework
for
holistic,
patient-centered
management
strategies
consider
various
contributing
factors
improve
health
outcomes.
Язык: Английский
Glucagon-like-peptide 1 receptor agonist for metabolic dysfunction-associated steatotic liver disease: hype or hope?
Singapore Medical Journal,
Год журнала:
2025,
Номер
66(4), С. 173 - 174
Опубликована: Апрель 1, 2025
Язык: Английский
Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Narrative Review
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(11), С. 5164 - 5164
Опубликована: Май 28, 2025
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
and
metabolic
steatohepatitis
(MASH)
are
spreading
worldwide
as
the
most
critical
causes
of
cirrhosis
hepatocellular
carcinoma
(HCC).
Thus,
improving
screening
managing
strategies
for
patients
with
MASLD
or
MASH
is
necessary.
A
traditional
non-systemic
review
provided
this
narrative.
Genetic
variations
associated
development
MASH,
such
PNPLA3,
TM6SF2,
GCKR,
MBOAT7,
MERTK,
HSD17B13,
were
initially
reviewed.
PNPLA3
genetic
variants
appeared
to
be
strongly
increased
pathogenesis
MASLD,
cirrhosis,
HCC.
We
also
reviewed
useful
polygenic
risk
score
(PRS)
their
related
occurrence
PRSs
better
predictors
HCC
in
than
any
single-nucleotide
polymorphisms.
RNA
interference
antisense
nucleotides
against
HSD17B13
being
developed.
Multidisciplinary
collaboration
cooperation
involving
hepatologists,
geneticists,
pharmacologists,
pathologists
should
resolve
complicated
problems
MASH.
This
narrative
highlights
importance
susceptibility
PRS
predictive
markers
personalized
medicine
future.
Язык: Английский
Alternative splicing: hallmark and therapeutic opportunity in metabolic liver disease
Gastroenterology report,
Год журнала:
2025,
Номер
13
Опубликована: Янв. 1, 2025
Abstract
Metabolic
dysfunction-associated
fatty
liver
disease
(MAFLD)
has
become
the
leading
cause
of
chronic
worldwide,
with
fibrosis
recognized
as
main
prognostic
factor
and
therapeutic
target.
While
early-stage
is
reversible,
advanced
poses
a
significant
clinical
challenge
due
to
limited
treatment
options,
highlighting
need
for
innovative
management
strategies.
Recent
studies
have
shown
that
alternative
pre-mRNA
splicing,
critical
mechanism
regulating
gene
expression
protein
diversity,
plays
fundamental
role
in
pathogenesis
MAFLD
associated
fibrosis.
Understanding
complex
relationship
between
splicing
progression
could
pave
way
novel
approaches
improve
outcomes.
In
this
review,
we
describe
intricate
mechanisms
MAFLD.
Specifically,
explored
pivotal
factors,
RNA-binding
proteins,
their
interactions
metabolic
epigenetic
regulators.
Furthermore,
provide
an
overview
latest
advancements
splicing-based
strategies
biomarker
development.
Particular
emphasis
placed
on
potential
application
antisense
oligonucleotides
rectifying
anomalies,
thereby
laying
foundation
precision
medicine
MAFLD-associated
Язык: Английский
Association between estimated glucose disposal rate and the risk of MAFLD in American adults: a cross-sectional study
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Июнь 2, 2025
The
estimated
glucose
disposal
rate
(eGDR),
as
a
novel
metric
of
insulin
resistance
(IR),
has
been
demonstrated
to
correlate
with
hepatic
steatosis
in
patients
diabetes.
Although
IR
is
considered
factor
affecting
lipid
metabolism,
the
correlation
between
eGDR
and
metabolic
associated
fatty
liver
disease
(MAFLD)
still
unclear.
Data
from
2017-2020
National
Health
Nutrition
Examination
Survey
(NHANES)
were
employed
this
cross-sectional
study
designed
examine
association
MAFLD
through
application
weighted
multivariate
logistic
regression
model.
nonlinear
relationship
was
described
utilizing
restricted
cubic
spline
(RCS).
Subgroup
analysis
performed
assess
consistency
results
causal
mediation
explore
potential
mediators.
included
3,585
participants,
2,002
whom
diagnosed
MAFLD,
prevalence
55.84%.
After
adjusting
for
all
confounding
factors,
risk
decreased
by
19%
each
unit
increase
(odds
ratio
[OR]
0.81,
95%
confidence
interval
[CI]
0.76,
0.88,
P
<
0.0001).
Analysis
quartiles
further
supported
finding.
revealed
significant
negative
MAFLD.
Causal
indicated
that
partially
mediated
atherogenic
index
plasma
(AIP),
8.75%.
Our
demonstrate
which
AIP
plays
mediating
role,
offering
new
insights
into
prevention
management
Язык: Английский